Our Experts

headshot-dinesh-kabaleeswaran

Dinesh Kabaleeswaran

Senior Vice President, Advisory Services

Expertise: AI, Policy and Regulation, Oncology and Rare Disease, Real-World Data, Contracting, Reimbursement and Rebates, Industry Trends, Commercial Strategy, Payer Market Research

Dinesh Kabaleeswaran is the senior vice president of Advisory Services at MMIT. His team provides market access context and a market research narrative for the company’s data and technology products. Dinesh has more than a decade of managed care experience, advising large biopharmaceutical clients on pre- and post-launch strategies across oncology, non-oncology and immunology therapeutic areas. Dinesh holds a master’s degree in Bioengineering from the University of Pennsylvania.

Insights by Dinesh Kabaleeswaran

Article | November 21, 2024

From Integration to AI: The Data-Driven Future of Market Access

In a competitive market, pharma companies are increasingly relying on various datasets to drive their decision-making. With so many disparate sources, however, data standardization presents a challenge, especially for companies eager to use predictive analytics tools.

On-Demand Webinar | August 5, 2024

Overcoming the Barriers to Patient Access in 2024 and Beyond

In this BioPharma Dive webinar, MMIT’s Dinesh Kabaleeswaran and Dedham Group’s Jen Klarer discuss insights from the 2024 State of Patient Access Survey, highlight challenges in cell and gene therapy, and explain how investments in real-world data (RWD) and AI are helping pharma organizations optimize market access strategies.

Article | November 10, 2023

Four Trends That Are Shaping the Future of Market Access

Stakeholders have had to adjust to new developments in the healthcare ecosystem such as the Inflation Reduction Act, the rise of immunology biosimilars and insulin price changes impacting payer rebate economics, and the recent ruling that insurers can no longer implement copay accumulator adjustor programs, among many others.

Article | May 18, 2023

How Real-World Data Helps Manufacturers See the Complete Market Access Story

In competitive therapeutic areas, like immunology and oncology, optimizing market share depends on creating a more structured, holistic market access story. By augmenting traditional market access datasets with real-world data from claims and labs, manufacturers can follow patients’ progression along the care continuum—and uncover new opportunities to improve access.

Article | January 5, 2023

What’s Ahead for Market Access in 2023?

Despite the challenges of the pandemic, the pharma industry has enjoyed steady growth during the past two years, which is expected to continue in 2023. The global pharmaceutical market is forecast to expand at a CAGR of 5.7% between now and 2028.
Stay In Touch

Be the first to know about new arrivals and promotions

Reducing Risk: 5 Steps for a Fearless Launch